CLAIMS

What is claimed is:

1. Use of an effective amount of an anti-CGRP antibody in the manufacture of a medicament for acute treatment of migraine in a patient, wherein the patient has a headache and wherein said medicament is to be administered to said patient within 30 hours of headache onset, preferably within 24 hours of headache onset.

2. The use of claim 1, wherein said anti-CGRP antibody administration begins within 18 hours, within 12 hours, within 6 hours, within 5 hours, within 4 hours, within 3 hours, within 2 hours, or within 1 hour of headache onset, such as between 1-6 hours from headache onset.

3. The use of any one of the foregoing claims, wherein said medicament is to be administered via intravenous infusion.

4. The use of any one of the foregoing claims, wherein said patient is free from the most bothersome symptom (MBS) at 2 hours post-completion of administration or infusion.

5. The use of any one of the foregoing claims, wherein said administration improves one or more of the following: time to pain relief; time to pain freedom; headache pain freedom at 2 hours with sustained headache pain freedom for 24 and 48 hours post completion of infusion; use of rescue medication by 24 hours and by 48 hours post completion of infusion; absence of photophobia at 2 hours post completion of infusion; absence of phonophobia at 2 hours post completion of infusion; absence of nausea at 2 hours post completion of infusion; change from baseline in Headache Impact Test (HIT-6) at Week 4; or change from baseline in Migraine Treatment Optimization Questionnaire-6 (MTOQ-6) at Week 4.

6. The use of any one of the foregoing claims, wherein said anti-CGRP antibody comprises the light chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 224; SEQ ID NO: 226; and SEQ ID NO: 228, respectively and heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 204; SEQ ID NO: 206; and SEQ ID NO: 208, respectively.

7. The use of any one of the foregoing claims, wherein said anti-CGRP antibody comprises the variable light chain polypeptide of SEQ ID NO: 222 and the variable heavy chain polypeptide of SEQ ID NO: 202.

8. The use of any one of the foregoing claims, wherein said anti-CGRP antibody comprises the light chain polypeptide of SEQ ID NO: 221 and the heavy chain polypeptide of SEQ ID NO: 201 or SEQ ID NO: 566.

9. The use of any one of the foregoing claims, wherein the anti-CGRP antibody is to be administered in an amount between 100 mg and 300 mg, or is about 100 mg, or is about 300 mg.